Drug Profile


Latest Information Update: 22 Aug 2007

Price : $50

At a glance

  • Originator Indena
  • Class
  • Mechanism of Action Apoptosis inhibitors; Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued CNS disorders; Pneumocystis pneumonia; Protozoan infections; Type 2 diabetes mellitus

Most Recent Events

  • 15 Oct 1998 A preclinical study has been added to the Neurological disorders pharmacodynamics section
  • 02 Oct 1997 A study has been added to the Diabetes pharmacodynamics section
  • 02 Oct 1997 Preclinical development for Type-2 diabetes mellitus in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top